STOCK TITAN

Boston Scientific Corp. - BSX STOCK NEWS

Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.

Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.

The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.

Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.

Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.

Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.

On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.

Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.

As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.

Rhea-AI Summary
Boston Scientific launches new employee resource group, FIRE, to foster Indigenous resources and empowerment in honor of Native American Heritage Month. The group has over 350 members and aims to share hidden Native American histories and important truths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
-
Rhea-AI Summary
Boston Scientific Corporation (BSX) will participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024. Mike Mahoney, chairman and CEO, will have a 30-minute Q&A session. A live webcast will be available on the Investor Relations section of the Boston Scientific website. The replay will be available one hour after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary
Boston Scientific's Social Change Champions program aims to provide leadership opportunities for employees while making a sustainable impact in the health equity space. The company's recent pilot program involved 12 employees traveling to Lima, Peru, to help Socios en Salud, a recent Signature Health Grant recipient, with challenges such as defining a growth strategy and providing crucial HPV testing for cervical cancer. The program resulted in action plans to eliminate inefficiencies and boost revenue, as well as the creation of FAQs to educate women on the importance of cervical cancer screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the fourth quarter and full year 2023, with net sales of $3.725 billion and $14.240 billion, respectively. The company achieved significant growth in net sales, GAAP net income, and adjusted EPS compared to the prior year period. The CEO, Mike Mahoney, expressed gratitude towards the global team for the exceptional results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
-
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, a new treatment for paroxysmal atrial fibrillation. The system uses non-thermal electric fields to ablate heart tissue, with positive clinical trial data and real-world use supporting its safety and efficacy. The system has also received Breakthrough Device Designation and CE Mark, with plans for immediate launch in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
Axonics, Inc. (AXNX) Reports Strong Revenue Growth in Q4 and FY23, Expects 27% and 34% Increases Respectively. Preliminary unaudited revenue for Q4 2023 is $109.3 to $109.7 million, an increase of 27% compared to the prior year period. Fiscal Year 2023 revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022. The company attributes the growth to higher utilization and share of wallet at existing customers and the onboarding of new accounts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
Rhea-AI Summary
Axonics, Inc. (AXNX) has entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business and has pioneered significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and urethral bulking for women with stress urinary incontinence. The transaction is expected to close in the first half of 2024, pending approval of Axonics’ stockholders and receipt of required regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
-
Rhea-AI Summary
Boston Scientific Corporation (BSX) to acquire Axonics, Inc. (AXNX) for $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' products include the Axonics R20TM and the Axonics F15TM Systems for sacral neuromodulation therapy, with expected high revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
-
Rhea-AI Summary
Boston Scientific Corporation (BSX) to host conference call on January 31, 2024, to discuss Q4 financial results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF). The trial aims to compare the outcomes of ablation with the FARAPULSE PFA System to anti-arrhythmic drug therapy commonly prescribed for patients with persistent AF. The company anticipates FDA approval of the system in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags

FAQ

What is the current stock price of Boston Scientific (BSX)?

The current stock price of Boston Scientific (BSX) is $90.45 as of November 18, 2024.

What is the market cap of Boston Scientific (BSX)?

The market cap of Boston Scientific (BSX) is approximately 133.8B.

What does Boston Scientific Corp. specialize in?

Boston Scientific specializes in developing, manufacturing, and marketing medical devices for interventional medical procedures, focusing on less invasive solutions.

What are the main segments of Boston Scientific?

The company operates through two main segments: MedSurg and Cardiovascular.

What recent financial achievement has Boston Scientific announced?

Boston Scientific recently completed a public offering of €2,000,000,000 in notes to finance the acquisition of Axonics, Inc. and to repay existing debt.

What is the AGENT™ Drug-Coated Balloon (DCB)?

The AGENT™ Drug-Coated Balloon is a novel device approved by the FDA to treat coronary in-stent restenosis in patients with coronary artery disease.

What is the focus of Boston Scientific’s latest clinical trials?

The NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System focus on improving patient outcomes and expanding product offerings.

How has Boston Scientific performed financially in 2024?

For the first quarter of 2024, Boston Scientific reported net sales of $3.856 billion, a 13.8% increase from the prior year.

What are some key products manufactured by Boston Scientific?

Boston Scientific manufactures products for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, and more.

How much of Boston Scientific’s sales come from international markets?

Nearly half of Boston Scientific's total sales are from international markets.

Who are Boston Scientific’s customers?

Boston Scientific markets its products to healthcare professionals and institutions globally.

What is Boston Scientific's vision for the future?

Boston Scientific aims to transform lives through innovative medical technologies that improve patient health and reduce healthcare costs.

Boston Scientific Corp.

NYSE:BSX

BSX Rankings

BSX Stock Data

133.82B
1.47B
0.18%
92.47%
0.88%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MARLBOROUGH